ReviewOpen medicine (Warsaw, Poland)2026
SMP30: a promising cancer biomarker with therapeutic potential.
Review in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: SMP30 is a calcium binding protein closely related to cellular senescence. Low expression of SMP30 is significantly associated with malignant progression and poor prognosis in tumors, suggesting it values as a potential diagnostic biomarker and therapeutic target. Content: We systematically review recent studies on SMP30 in human tumors, highlight its role in modulating tumor cells proliferation and apoptosis, and detail mechanism of its involvement in glycolipid metabolic reprogramming as well as its impact on the tumor microenvironment and metastasis. Summary: SMP30 is involved in regulating cell cycle, maintaining intracellular homeostasis, and protecting cells from external damage. It supports cellular homeostasis and resistance to apoptosis by modulating intracellular Ca Outlook: SMP30 is a key regulator of cellular senescence with significant implication in tumorigenesis. Low expression of SMP30 relates to multiple oncogenic mechanisms, including cell cycle, apoptosis, metabolic reprogramming, epithelial mesenchymal transition (EMT), and immune evasion, which shows promising potential for early diagnosis, prognostic evaluation, and targeted therapy of cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.